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ABSTRACT OF THESIS

SURFACE MODIFICATION OF PLGA BIOMATERIALS FOR SITE-DIRECTED
IMMOBILIZATION OF GROWTH FACTORS
Biodegradable polymer materials, specifically poly(lactic-co-glycolide) (PLGA) can be
used as bone replacements for bone regeneration. Scaffolds can be prepared to be porous
to induce bone growth into a scaffold so that it is replaced with natural tissue as the
polymer degrades. However, simply using PLGA will result in formation of scar tissue
rather than regeneration of natural bone. Therefore focus has turned to attaching growth
factors to the PLGA molecules to elicit a specific cellular response when the implant is
placed in the body. Site-directed immobilization utilizes specific groups on both the
biomaterial and biomolecule so that growth factors can be oriented in a specific manner
for increased cellular response. In this research, exposed carboxyl groups on a non endcapped PLGA were modified with bishydrazide spacer molecules of varying length for
the eventual attachment of a biomolecule via carbodiimide chemistry. The number of
hydrazide groups attached to the surface could be controlled to investigate the effects of
the spacer length on protein immobilization. Both vascular endothelial growth factor
(VEGF) and parathyroid hormone (PTH) were used in these studies. These two
molecules have different target cells and actions, although both can play a role in bone
formation. Both molecules have carbohydrate residues that were oxidized with periodate
to form aldehyde moieties that were able to react with the hydrazide spacers to form a
stable bond between the spacer and protein. The use of a spacer enhanced the binding
accessibility of the protein as compared to randomly adsorbed protein. The shortest and
longest of the spacers resulted in the highest amount of protein, with corresponding
results for antibody binding. The modification of PLGA functional groups with a spacer
molecule indicates that this material could be used for site-directed immobilization for
any application, simply by tailoring the reaction between the biomaterial and
biomolecule.
KEYWORDS: PLGA, surface modification, growth factors, drug delivery, scaffold
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1. INTRODUCTION

Bone is a unique site for implants as loading directions and forces vary depending on
where implants are located in the body [1]. Used as bone replacements, these substitutes
must be able to withstand high loads and activity levels in a range of directions. For
orthopedic repair, the age range of patients is large, as is the activity level, forcing any
implant to be able to withstand many loading conditions [2]. Bone constantly undergoes
different reactions in its modeling and remodeling due to the forces and stresses put on it
[3]. This bone regeneration is not able to heal critical size defects, secondary to diseases,
tumors and nonunion fractures. Critical size defects are large defects resulting in
competition between bone and soft tissue to repair the defect [4]. Of the 6.5 million bone
fractures suffered annually in the U.S., 10-15% of these are nonunions [5]. These
nonunion fractures often require surgical intervention because the fracture is not able to
heal properly.

Bone grafting procedures are very commonly used to treat bone defects; in fact more than
500,000 of these procedures are performed each year in the U.S [6]. There are a few
types of natural bone grafting techniques, autografts, allografts and xenografts. An
autograft uses the patient’s own bone from another site, whereas in an allograft, a donor
tissue from the same species is used and bovine tissue is used in xenografts. There are
major limitations to all of these surgeries. Autografts require two painful surgical sites
with a limit on the amount of bone that can be taken from the donor site, usually the iliac
crest [7]. Allografts can be characterized by limited supply, possible rejection of donor
tissue and possible transmission of disease. Xenografts increase the risk of disease
transmission, as well as rejection of donor tissue from another species [3]. Therefore the
focus of treating bone defects has turned to the development of synthetic substitutes [7].

Synthetic bone substitutes range from permanent to resorbable materials and include
metals, glass, ceramics, polymers and composites of all of these materials. However,
these materials were not originally designed for contact with the human body and fibrous
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tissue can be formed when they come into contact with the body. The goal of a bone graft
is to restore function to the site of implantation, and ideally the defect will be replaced
with native bone not fibrous tissue, so a regenerative response to the implant is desired
[8]. To improve response to any of these materials, the presence of specific proteins, e.g.,
growth factors, can be used to control the body’s response to the implant immediately
after implantation [9].

The presence of specific proteins, such as bone morphogenetic protein-2 (BMP-2) and
insulin-like growth factor (IGF), can recruit cells to the site of the defect and signal
specific cellular responses, in order to promote the healing of bone defects [9, 10, 11].
These growth factors can be delivered using a systemic or local approach. Growth factors
can be delivered more efficiently if they are placed directly on the surface of the implant,
rather than a systemic delivery. Because of the short plasma half-life of these molecules,
it is difficult to maintain an effective dose of growth factors at the defect site using
systemic delivery [12, 13]. Therefore, it is more appropriate to use a local delivery
approach, which can maintain a specific dose of the growth factors or drugs at the defect
site.

One method to deliver growth factors to the site of the implant is to simply adsorb protein
onto the surface of implant. This technique is not at all controllable, so it is more useful
to have an immobilization method. One advantage to certain immobilization techniques is
that they can allow for specific orientation of growth factors so binding sites on the
growth factor are easily accessible to cells that encounter the implant [14]. There are two
different methods for immobilization: physical and chemical pathways. The physical
method utilizes electrostatic, hydrophobic/hydrophilic and van der Waals forces. This
may result in protein leaching as well as multiple binding points between the protein and
surface. The chemical method is carried out through the formation of a strong covalent
bond between the protein and the surface. This can result in a change in the structure of
the immobilized protein, although this can be done in a controlled manner, to create a
site-directed immobilization [14]. Expanding this chemical method, a spacer molecule
between the protein and the implant surface can be used. Using a spacer between the
2

material and the biomolecule can prevent crowding of the biomolecules and can help
with accessibility of the protein for interaction with the cells. Using the spacer arms will
allow for organization of the growth factors in such a way as to mimic the extracellular
matrix of cells [15].

The objective of this research study was to develop methods for site-directed
immobilization of bone growth factors on a biodegradable polymer. This was
accomplished by using specific functional groups on the polymer and spacers molecules.
Spacers were attached to the carboxyl groups on the polymer chains, and then growth
factors were attached to these spacers in an oriented manner.
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2. BACKGROUND AND SIGNIFICANCE

More than 500,000 bone grafting procedures are performed annually in the United States;
these bone grafting procedures are most commonly autografts, allografts, xenografts and
biomaterial implantation to repair a bone defect [6]. Autografts use a sample of bone
from the patient receiving the graft. Of course there are many limitations to this
technique, including the requirement of two surgical sites as well as donor site morbidity,
although this is still the gold standard for bone defect repair [3, 16, 17]. Allografts use a
donor tissue from another subject of the same species. Disadvantages of allografts
include rejection of donor tissue, transmission of blood-borne diseases and infection as
well as a limited supply of tissue [3, 16, 17]. Xenografts use an implant material from an
animal of a different species. There are many drawbacks to using this treatment due to
disease transmission, as well as possible rejection of donor tissue [3, 16, 17]. Many
synthetic materials have been used for implantation into the body. However, since they
were not designed for contact with the human body, a repair response rather than a
regenerative response is the end result [8, 18]. If the response is a repair, the defect site is
replaced with scar tissue, in contrast to regenerative results in which the defect is
replaced with native tissue. Synthetic materials may also be characterized by long-term
failure due to a mismatch in the mechanical properties between the implant and the
body’s natural tissue [19].

In order for a synthetic material to be appropriate for use as a biomaterial, there are
several criteria for creating a biomaterial which can elicit a specific response from the
body. These include: biocompatibility, specific architecture, osteoconduction,
chemotaxis, angiogenesis and vascularization, controlled delivery of protein/drug, and
administrative issues [20]. Biocompatibility is an important factor for any substance not
natural to the body to be used for in vivo applications, whether it is permanent or
temporary. It is defined in terms of the success of the implant to fulfill its intended
function and is considered a two way process. For bone implants, the biomaterial must be
able to withstand load bearing cycles without fatigue or wear, transfer appropriate loads
4

from the implant to bone. Both the entire implant and the implant-bone interface must be
evaluated for the criteria of biocompatibility to be met [3]. Cyto-compatibility is
important for in vitro testing of interactions between materials and cells. The implant
must not cause harm to the body in the form of cell or tissue death from toxicity and must
not elicit an immunological response [21]. These problems are usually tested using in
vitro techniques. Specific architecture is an important aspect which changes based on
where the implant is to be used. For example, biomaterials which will be used in loadbearing applications must have a specific shape to match the defect as well as high
amount of strength. Non-load bearing applications also require a specific shape to match
a defect but do not require as high of strength as load-bearing applications [22]. However,
a bone replacement must not only have the same amount of strength as the natural
material it is replacing, it must actually have a higher amount of strength. This is because
implants lack the ability to repair localized damage due to fatigue [23]. In addition, the
architecture of biomaterials must have porosity to allow for bone growth into the scaffold
and transport of nutrients and waste products within the implant [21]. Osteoconduction is
a three-dimensional process of promoting bone formation and is observed when an
implant is placed into or adjacent to bone tissue [24]. In the process cells proliferate into
the material, whether through porosity or simply on the surface, and begin either a repair
or regenerative response [8]. Chemotaxis is the directional movement of cells in response
to a chemical stimulus. Chemotaxis is required for cells to bind to receptor sites on the
implant to perform a specific function, such as building bone [25]. Angiogenesis and
vascularization are the formation of new blood vessels and their proliferation into an
implant, which is an important aspect of wound healing. The presence of blood cells
results in better healing, because when any implant is placed in bone an injury occurs [9].
If a specific response from the implant is either required or desired, it may be desired to
use the biomaterial as a vehicle for protein or drug delivery. If this is the case, the
biomaterial must be able to release the protein or drug at specific intervals and maintain
the concentration over a desired period of time [26]. Administrative issues are important
for the ease and quality control of preparation of any biomaterial. The biomaterial must
be able to modified to be a specific size or shape, as well as control of any modification
of the biomaterial.
5

2.1 Biomaterials
Currently there are permanent and biodegradable synthetic implants used in orthopedic
surgeries to treat bone defects. Common uses of permanent implants include hip and knee
replacements and some screws and plates for fracture fixation. Some biodegradable
materials may be converted to water-soluble material through both physical and chemical
processes. These biodegradable implants are often used in fracture nonunions as a filler
material until the defect may be replaced with host tissue. They can also be used as drug
delivery devices and coatings on permanent implants to improve bone attachment to an
implant [26]. Even though these biodegradable implants are not permanent, they still
must be biocompatible with natural tissues. They must be biocompatible from the initial
time of implantation until they have completely degraded [24]. This requirement
complicates the use of certain biodegradable implants as they may release acidic
byproducts that can be harmful to tissues and cells as they degrade [21]. However, it is
important to note that using a biodegradable implant eliminates the long-term
disadvantages of using permanent synthetic material because degradable implants are
usually replaced with host tissue [19]. When any material comes into contact with the
body, a strong and immediate reaction by the body is necessary for the implant to be
incorporated into the body and serve the function for which it was intended.

As previously mentioned, most of the current implant materials were not designed for
implantation into the body. However, some of these materials may be more useful for
implantation into the body than others, in that some materials may be able to elicit a
specific and desired host response when they are implanted. Metals, such as titanium, are
widely used for orthopedic implants into bone, but these metals have such different
properties than bone that the material can actually weaken the bone surrounding the
implant through stress shielding [27]. Stress shielding occurs when load is transferred to
the implant rather than the surrounding bone. Bone requires load in order to maintain its
strength through the constant remodeling it undergoes in response to force. With reduced
force, there is less need for bone to maintain its strength, and the ultimate result of the
bone remodeling process is net bone loss [3]. Ceramics, such as hydroxyapatite and
tricalcium phosphate, can be processed under high temperatures and pressures to form a
6

dense ceramic and are characterized by brittleness with low resistance to impact [17, 28].
These dense scaffolds may also degrade over a period of months to years [29]. These
same ceramics can also be processed to be porous, but may result in rapid dissolution, as
short as six weeks [30]. However, polymers are now being investigated for use as
orthopedic implants. Poly(glycolic acid) (PGA) is an FDA approved polymer for
resorbable sutures. Poly(lactic acid) (PLA) is a similar polymer that is used for screws
and plates in bone repair devices. However, combining both of these polymers to create a
copolymer, poly(lactic-co-glycolide) (PLGA), creates a strong resorbable implant for
bone replacements with controllable properties. The crystallinity, strength and
degradation are controlled by the ratio of LA to GA [31, 32]. It is also possible to modify
the end of each polymer chain in order to change the polymer properties through function
groups present on polymers [33]. Many PLGA chains have an aliphatic end-cap that
makes the polymer more hydrophobic and drastically increases the length of degradation
as compared to a polymer chain without an end-cap. While all PLGA chains are
hydrophobic, the presence of an end-cap makes the polymer considerably more
hydrophobic than PLGA chains without the end-cap. These more hydrophobic polymers
also have a lower acid number as reported by Schrier [34]. When the carboxyl group is
exposed, the acid number, which is an indication of the amount of basic solution required
to neutralize one gram of PLGA, may increase by a factor anywhere from 2 to 15 times
[34]. These simple changes to the polymer chain, by addition or subtraction of an end-cap
and the ratio of GA to LA, are important because they make the polymer a more versatile
implant for many different applications, including orthopedic devices, dental implants,
and even vascular implants. PLGA has been found to be osteoconductive and is therefore
suitable for bone replacement in the form of microspheres, coatings and scaffolds.

2.2 Growth Factors
Growth factors are designated as polypeptides that are able to transmit a signal in order to
modulate cellular activities and promote cell proliferation [13, 35]. They play an
important role in development and wound and fracture healing by recruiting appropriate
cells to a specific site at necessary times. For example, immediately after a fracture has
7

occurred, natural wound healing begins. Initially, platelets aggregate to stop blood loss,
while chemotaxis of neutrophils and monocytes into the blood clot occurs. Fibroblastic
growth factor (FGF) stimulates fibroblasts to produce proteins to stabilize the fracture.
Bone morphogenic protein (BMP) is found in mesenchymal cells in the hematoma and
the periosteum adjacent to the facture. Transforming growth factor (TGF) and platelet
derived growth factor (PDGF) are released by platelets and inflammatory cells into the
fracture hematoma to stimulate proliferation of mesenchymal cells into the periosteum.
PDGF is also found in macrophages near the periosteum two day after fracture but
decreases after that [25]. Chondrocytes also organize the initial collagen matrix into a
cartilage framework so that differentiated osteoblasts can remodel the framework into
bone. These growth factors help to promote osteoblasts differentiation to build bone and
repair the fracture. Concentrations of growth factors decrease as the bone matures.
Healing continues over several months of bone remodeling [5].

Effects of growth factors are also concentration dependent and are able to influence both
secretion and action of other growth factors. This is done through one growth factor
stimulating another cell to produce and secrete a specific growth factor, often as part of a
cascade of wound healing or other specific events involved in development. Growth
factors are able to act on the cell that secreted them (autocrine), a nearby cell (paracrine),
a distant cell of a different phenotype (endocrine) [9, 25].

As an effort to improve bone defect healing, growth factors have been added to implants
prior to implantation. The adsorption of growth factors, including BMP, FGF, TGF,
PDGF, (FGF), can improve osteointegration of the implant into bone [9, 25]. The release
of these growth factors helps to regulate cellular activity. It has been shown that only
BMP’s are able to differentiate mesenchymal cells into osteoblasts as well as stimulate
cell growth and bone formation [9, 35, 16]. The concentration of the growth factors is
also very important, as at time of implantation, a high concentration of BMP is required
to encourage differentiation of recruited cells into osteoblasts, whereas the concentration
of other growth factors is important further from the time of implantation for the
osteoblasts to continue to build bone [25]. Biomaterials allow growth factors to be
8

maintained at the implant site for an extended period of time rather than in a systemic
delivery when concentrations dissipate quickly.

Vascular endothelial growth factor (VEGF) is an endothelial cell mitogen and motogen
and is often expressed in vascular processes. It is secreted by endothelial cells,
osteoblasts and some macrophages and helps to stimulate the growth of any type of blood
cells during angiogenesis and vasculogenesis processes [36, 37]. VEGF is a key regulator
in angiogenesis. VEGF was initially identified through its actions on vascular endothelial
cells, although, it is also expressed in the inflammatory responses, which is a natural part
of wound healing [37]. It has also been shown to be chemotactic for monocytes and
osteoblasts [36]. Some preliminary studies have shown that in the presence of BMPs,
VEGF may play a role in bone regeneration through aiding in recruitment of
mesenchymal stem cells, enhance cell survival and prevent cartilage formation in the
place of bone formation [38]. In addition, VEGF has been found to be useful in bone
regeneration through the process of angiogenesis. The presence of VEGF on PLGA
scaffolds enhanced mineral tissue regeneration in a rat cranium critical defect. This
enhancement of mineral tissue regeneration resulted in increased regeneration of the
osteoid matrix [39].

Parathyroid Hormone (PTH) is normally secreted by the parathyroid gland in response to
low plasma calcium level. PTH serves to regulate calcium homeostasis in three ways:
stimulating bone resorption, increasing calcium absorption in the intestines and
increasing calcium and phosphate resorption in the kidneys [40]. When there are high
levels of PTH, bone resorption begins resulting in bone mass loss. However, an absence
of PTH results in lack of bone growth. It has been determined that low, intermittent doses
of PTH stimulate osteoblastic activity to replace bone loss [12]. PTH also works to
increase bone mass by acting as an inhibitor of normal bone resorption [40]. The 34
amino acid sequence of PTH (1-34) is the section that is thought to have these effects
[40]. The challenge to using PTH in cases of bone loss is to maintain a very low level
dose of PTH or intermittingly high doses [12].
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Systemic oral delivery of growth factors is not ideal due to low bioavailability based on
the protein’s enzymatic degradation and poor absorption. Intravenous delivery of growth
factors has also been explored, but again is not very effective because of the short plasma
half lives [25]. For example, PDGF can not be detected in the circulation after IV
delivery, due to its half life of two minutes when delivered in this form [13]. Because
concentration of the growth factor plays a role in its behavior, more frequent dosing by
both of these systemic delivery methods would be required to reach an effective dose in
the body [34]. Parathyroid hormone (PTH) has been found to have bone forming effects
if a high dose is present for a short period of time or if a low dose is maintained for a
short amount of time, otherwise bone resorption effects are seen [12]. Low doses can be
maintained at the implant site if PTH is adsorbed onto the surface of the implant. Fracture
nonunions have been shown to have poor bone stock, scar tissue and vascularity, and a
one-time dose of BMP is not sufficient enough to stimulate bone formation. In contrast,
maintained delivery of BMP directly to the site of implantation stimulates bone formation
more than a systemic delivery [10, 41]. However, simply adsorbing growth factors onto
the implant does not allow for controlled drug delivery, so the focus of drug delivery has
turned to immobilizing growth factors onto or within the implant.

2.3 Immobilization Techniques
Currently there are several ways to attach growth factors to biomaterials. Some are very
simple techniques, while some are more difficult to accomplish, but may or may not yield
better results. The three ways of attaching a biomolecule are through the use of physical
adsorption, physical “entrapment”, and covalent attachment [3]. The most simple of these
techniques is physical adsorption. This is usually carried out by simply soaking the
implant in a solution of the molecule to be attached, and the biomolecules attach to
functional groups on the surface, in addition to the possibility for liquid to be maintained
within pores of some implants. This method allows for no control over the amount or
orientation of biomolecules on the implant. Physical entrapment is not ideal because of
the high shear forces and strong solvents that are often required for the development of
biodegradable implants [34]. Conditions such as these can damage the protein, thereby
10

reducing its bioactivity and may also reduce the loading efficiency of the protein onto the
biomolecule [34]. Finally, covalent attachment of proteins is carried out using hydrogels,
solid surfaces and soluble polymer conjugates, all with functional groups which allow the
biomolecule to interact and form a stable, covalent bond [3, 33]. This can lead to
permanent or temporary presence of the biomolecule. For example, attaching a large
biomolecule to a solid surface can lead to a long standing retention. Using a
biodegradable system, such as PLGA, the biomolecule can be released as the polymer
degrades and the biomolecule can advance the replacement of the implant with native
tissue [42].

Random approach to protein immobilization results in some of cell-receptor binding sites
being inaccessible to cells and possibly directed towards the biomaterial rather than cells.
Random immobilization can be the result of very simple methods such as soaking a
biomaterial in a protein solution. Covalent attachment, through surface exposed
functional groups can lead to the immobilization of protein onto the surface of a
biomaterial in which the biomolecules are randomly oriented or have the same
orientation, as shown in Figure 1. This is a temporary or permanent localization of the
biomolecule onto a biomaterial (or support). In the schematic with randomly adsorbed
protein, the cell binding sites are all oriented in a different direction, which could make it
difficult for cells to see and interact with the cell receptor binding sites, whereas in the
oriented immobilization, all of the binding sites are directed in the same way, making it
easy for cells to respond to these sites [14]. Immobilization is becoming widely used
because the molecule (or cells) can be attached in such a controlled way so as to elicit a
specific response from the body when attached.

One method of immobilization utilizes carbodiimide (CDI) chemistry in one or two steps
to couple amines and carboxyl groups [33, 43, 44]. CDI is one of the more useful
methods for modifying carboxyl groups. However, diazoalkane and carbonyldiimidazole
processes can also be used. Diazoalkanes are amides and esters which are able to react
spontaneously with carboxyl groups to form ester bonds. However, at acidic pH, crossreaction with sulfhydrl groups can occur, and as pH increases the reaction becomes less
11

specific. Carbonyldiimidazole has two leaving groups of aculimidazole that react with
carboxyl groups and produces carbon dioxide and imidazole. The carboxyl group can
then react to form amide or ester bonds. CDI is used to mediate the formation of amide
bonds between carboxyl groups and an amine. The reaction forms an intermediate, oacylisourea that is highly reactive. The carbonyl group of this ester is attached by an
amine nucleophile to form an amide bone [45]. In the single step version, both CDI and
the biomolecule interact with the biomaterial simultaneously. However, in the two step
process, first the CDI molecule interacts with the biomaterial to activate groups for
protein attachment, and is removed. Following removal of CDI solution, the biomolecule
is allowed to interact with the biomaterial. In both cases, protein immobilization is the
result. This immobilization allows retention of the biomolecule on the surface when in
contact with medium [43].

Random
receptor-binding
site

biomaterial

Oriented
receptorbinding
site

biomaterial

Figure 1: Schematic depicting protein adsorption, randomly (top image) with receptor
binding sites oriented in different directions and oriented immobilization (bottom image)
with all of the binding sites oriented in the same way
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In a study by Puleo et al, BMP was immobilized onto the surface of a titanium alloy. The
alloy was functionalized with different amine concentrations for immobilization of the
BMP molecule. The immobilization was carried out using a two-step CDI process to
activate the amine groups on the alloy surface. Then BMP was attached to the activated
intermediate groups. BMP was also randomly adsorbed onto the surface of the titanium
implant by soaking the implant in a solution of BMP for two hours. Initially the alkaline
phosphatase activity was highest on surfaces with randomly adsorbed protein; however,
after overnight incubation to remove loosely bound protein, the immobilized surfaces had
a significantly higher activity [43].

Site-directed immobilization results in biomolecules being attached to surfaces of implant
materials in a controlled and specific oriented manner. This allows for these growth
factors/proteins to be oriented in such a manner that all of the cell receptor-binding sites
on the biomolecule are accessible to the cells. Site directed immobilization is achieved by
altering the surface of the biomaterial and/or the biomolecule. This can be done using
specific functional group on the biomaterial to be reactive with specific functional groups
on the biomolecule. For example, a glycoprotein has at least one oligosaccharide unit that
is linked covalently to carbohydrate residues on amino acids. These carbohydrate
residues can be specifically oxidized to aldehydes. A condensation reaction with
hydrazide groups on the biomaterial results in hydrazone bonds between the protein and
biomaterial [14].

Site-directed immobilization is already very controlled; though a spacer molecule can be
used between a biomolecule and the biomaterial surface. The use of a spacer molecule is
illustrated in Figure 2. The spacer is simply a molecule that is homo- and heterobifunctional, such that it may attach itself to the biomaterial and biomolecule. Use of
spacers reduces steric hindrance for both large and small biomolecules, allowing for a
greater amount of specific bioactivity. Attaching small molecules further away from the
biomaterial surfaces allows cells to react with receptor-binding sites that have become
more accessible. For large molecules, the use of a spacer can help to prevent interaction
and crowding between the individual molecules. Using a spacer that is too short may not
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prevent the crowding of the molecules as they would be so close to the biomaterial
surface. Also, using too long of a spacer may prevent loss of the biomolecule and poor
cell proliferation into a biomaterial. The use of a biodegradable spacer can also control
the release of the biomolecule from the surface of the biomaterial. Thus, these spacers
can be designed to operate for orthopedic coatings and implants, diagnostic tools and
potential drug delivery systems by creating a material with both a traditional purpose as
well as a biological function instead of a simple block of material implanted into the
body.

Surface Density

Spacer

Spacer

Spacer

Spacer

Spacer

Spacer Length

Spacer

Spacer

Spacer

Spacer

Spacer

Spacer

Spacer

Spacer

Spacer

Figure 2: Schematic of protein attached to biomaterial using spacers with varying surface
density (left) and varying spacer length (right)

While PLGA simply by itself has been shown to be osteoconductive, there is not a strong
therapeutic response by the body to the polymer implant into bone [17]. PLGA offers
very little reason for cells to be recruited to the surgical site, other than for repair
response. However, the functional groups at the end of the polymer can be very useful in
creating a controlled implant for repair of bone defects [33]. A polymer without an
aliphatic end cap exposes a carboxyl group at the end and makes modification simple by
altering this group. Therefore each polymer chain can be modified to attach a specific
growth factor to its end and control the concentration and orientation of these
immobilized growth factors. For example, in a study by Yoo et al, hyaluronic acid (HA)
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was immobilized on the surface of PLGA for the purpose of cartilage regeneration. The
PLGA scaffolds were prepared by blending PLGA with an amine-terminated PLGA-PEG
di-block polymer. The HA molecules were chemically conjugated to the surface-exposed
amine groups on the scaffolds, and allowed to interact with the PLGA surface, thereby
immobilizing HA onto the surface in an oriented manner. When scaffolds were seeded
with chondrocytes, enhanced cellular attachment was seen for the modified PLGA
surfaces in comparison to unmodified. Collagen synthesis was also improved [46].

In a study by Hu et al chemically inert PLA porous films were activated with plasma NH3
and then an RGD sequence or poly(L-lysine) was attached in an oriented manner.
Following attachment of RGD or PLL the films underwent cell culture with osteogenic
precursor cells (OPCs) and alkaline phosphatase (AP) activity and extracellular calcium
were measured. Attachment of the RGD resulted in a higher amount of AP activity than
did the PLL groups. Calcium levels were also higher after 28 days of incubation for
scaffolds with attached RGD groups. These levels are proportional to the number of
differentiated bone cells. The presence of the RGD groups resulted in a significantly
higher number of bone cells present in comparison to films with immobilized PLL or
control. These scaffolds were only tested in vitro so further testing is required to
determine if the same results would be found in vivo [47].

PLGA releases protein from the scaffold through a bulk process of degradation when low
levels of growth factors are used [48]. Using a spacer between the polymer and the
growth factor allows for even more control by preventing overcrowding effects from too
much of the growth factor and also makes it easier for cell receptors to respond to the
presence of the growth factors.

2.4 Significance
The need for bone biomaterials is rapidly rising with an aging population. No one
biomaterial has been proven ideal for bone implantation. The addition of an immobilized
growth factor, drug or protein onto the surface of any biomaterial can help with any
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application in the body. By using a functional group at the end of a polymer, or any
resorbable material, the surface can be modified to allow for the presence of specific
proteins or drugs that are delivered directly to a specific site. Using a spacer allows for a
controlled response by the cells near the implant and can affect healing of the specific
wound or diseased site. By altering the biomaterial, proteins, spacer length and density,
this idea can be applied to any material implanted into the body.
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3. MATERIALS AND METHODS

3.1 Polymer
The polymer investigated was poly(D,L-lactide-co-glycolide) (PLGA), obtained from
Alkermes (Wilmington, OH). This particular polymer (DL 2A) is a 50:50 copolymer ratio
of lactic and glycolic acid, and is non-endcapped, meaning that it has an exposed
carboxylic acid group at the end of the chain, which will be used for further surface
modification steps. The structure is shown in Figure 3.
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Figure 3: Structure of PLGA used in these studies

The molecular weight of the polymer was 11 KD. This polymer can easily be made into
coatings, microspheres and scaffolds for various applications. The glass transition
temperature, which was important for preparing scaffolds, was 41.3°C.

3.1.1 Coatings
Coatings were used for experimentation due to their ease of preparation and
measurements. Glass coverslips with a diameter of 12mm were investigated following a
simple coating technique. A 0.117% (w/v) polymer solution was made by dissolving
200mg into 1.7ml of methylene chloride (Sigma-Aldrich, St. Louis, MO). The solution
was vortexed and sonicated at 25W for 30 seconds. Approximately 30 to 40µL of this
solution was then dropped onto the top surface of each coverslip. Each coverslip was
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allowed to air dry for about 30 minutes and then vacuum-dried overnight or until ready
for use.

3.1.2 Microspheres
Microspheres were prepared using a water/oil/water (double) or water/oil (single)
emulsion technique. The 0.117% (w/v) polymer solution was prepared in the same
fashion as in the coatings method, by dissolving 200mg or PLGA into 1.7ml CH2Cl2. For
double emulsion techniques, 200µl of water was added to the polymer solution. For both
double and single emulsion techniques, the polymer solution was vortexed to dissolve the
polymer and then sonicated at 25W for 30 seconds. The solution was then added
dropwise to a 1% polyvinyl alcohol (PVA) (Sigma) solution. The PVA solution was
spinning at 700rpm, which was a fast enough rate to allow delivery of the polymer
solution directly to the bottom of the beaker. The rate was then slowed to approximately
600rpm and allowed to spin overnight until all of the CH2Cl2 had evaporated.
Microspheres were vacuum filtered using #40 Whatmann filter paper, washed with
deionized water and then vacuum-dried overnight and stored in the freezer until ready for
use.

3.1.3 Scaffolds
Scaffolds were prepared using a simple sintering process adapted from Borden et al [7].
Prepared microspheres were gently disaggregated from one another using a mortar and
pestle. Next, they were sieved to achieve a similar size range to one another, of about 50150µm. Two different masses of microspheres were used for scaffold preparation, both
50mg and 25mg.

The height of the scaffold was dictated by the size of the mold, mass of microspheres,
temperature and time of heating. The 50mg scaffolds were prepared by adding this mass
of sieved microspheres to a mold with a diameter of approximately 6.2mm. Initially
25mg scaffolds were also prepared using this mold, but later a mold with a diameter of
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4.2mm was used for the smaller scaffolds. As mentioned previously, the glass transition
temperature of the polymer was 41.3°C, so microspheres were heated in the mold at 50°C
for one, two or three days. This time and temperature was chosen to achieve a balance
between porosity and compressive strength.

3.2 Material Characterization

3.2.1 Scanning Electron Microscopy (SEM)
Microspheres and scaffolds were both examined using SEM techniques. Microspheres
were mounted onto a graphite “sticky pad” on an SEM stub. Scaffolds were fractured and
then mounted onto the stub using colloidal graphite. Each sample stub underwent gold
sputter coating in an argon atmosphere using the Emscope sc 400. Samples were then
examined with the Hitachi S-3200 (Tokyo, Japan) using an accelerating voltage of 5kV.

3.2.2 Mechanical Testing
Mechanical testing was carried out using a system created in the Center for Biomedical
Engineering. Linear force was applied through a stepper motor (model 801B-AM), digital
linear actuator with 45 lbs maximum linear source (Eastern Air Devices Corp., Dover,
NH). Displacement was measured with a DC linear variable differential transformer
(model 0244-00000; Transtek, Tuscon, AZ) with a maximum working range of ±1 inch
and had 0.5% error introduced by non-linearity over its working range. Load was
measured by a subminiature load cell (Entran, Fairfield, NJ) that introduced 1% error for
non-linearity over its working range and exhibits a 2.5% thermal sensitivity shift at 50°C.
The system was computer-controlled using LabView (National Instruments, Austin, TX).
Samples were loaded in compression until failure occurred. Compression data was
recorded and then transferred to a Microsoft Excel spreadsheet as force and displacement.
Within known height and diameter of the scaffold, a stress-strain plot was generated to
calculate the ultimate compressive strength and compressive modulus. An example of the
force-displacement plot generated from the apparatus is shown in Figure 4.
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Figure 4: Stress-strain plot for compression testing of a 50 mg scaffold heated for three
days at 50°C

3.2.3 Porosity
The porosity of scaffolds was measured using the Archimedes method in which the
scaffolds were immersed in 2ml ethanol and shaken slightly in addition to repeated cycles
of vacuum to force ethanol into the pores. Initially, 2ml of ethanol was placed in a small
graduated cylinder; this volume of ethanol was recorded as V1. A scaffold was then
placed in the graduated cylinder; the total volume of ethanol and scaffold was recorded as
V2. The scaffold was then removed from the ethanol. The remaining amount of ethanol in
the graduated cylinder was recorded as residual volume, V3. The porosity of the scaffold
was calculated using the following equation [49].

ε (%) =

V1 − V3
∗100
V2 − V3

3.2.4 Surface Area
Surface area was measured through nitrogen gas adsorption. Scaffolds were placed under
vacuum for a minimum of three days at room temperature and then outgassed overnight
at 25°C to remove any air from the scaffold. In order to measure the surface area of the
scaffolds, six scaffolds were used in each tube to ensure that a high enough surface area
was available for measurment using the TriStar 3000 from Micromeritics (Norcross,
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GA). The samples were outgassed at 25°C for 24 hours. Surface area was calculated
using BET isotherms.

3.3 Surface Modification
Modification of the carboxyl groups of PLGA was carried out using both coverslips and
scaffolds. Four different bishydrazides of varying length were investigated: oxalic
(Aldrich, Milwaukee, WI), succinic (Aldrich), adipic (Sigma) and sebacic bishydrazide
(TCI America, Portland, OR). Each of these has the same basic backbone, with varying
carbon chain lengths at their center. The structures are shown in Figure 5.
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Figure 5: Structure of bishydrazide spacer arms

The bishydrazide concentrations investigated were 0.002, 0.011, 0.018, 0.057, 0.115,
0.184mM dissolved in 0.1M 2-(N-morpholino)ethanesulfonic acid (MES) (Sigma) at a
pH of 6.0. One scaffold or coverslip sample was placed in each well of a 24 well plate.
Then 0.5ml of one of the bishydrazide solutions was added to the well. A solution of 1ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDAC) (Sigma) and nhydroxysuccinimide (Fluka, Buchs, Germany)was used to activate surfaces. This solution
was prepared to be 16mg/ml in a 0.1M MES (pH = 6.0) buffer solution. The EDAC/NHS
was prepared to be a 5:2 EDAC: NHS molar ratio and 0.5ml of this solution was allowed
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to react with the PLGA surfaces [43, 45]. Plates were then shaken at room temperature
for two hours. After activation the bishydrazide molecule attaches at the end of the PLGA
via a nucleophile reaction mechanism by adding 0.5ml of hydrazide solution to each
coverslip. A schematic of this entire reaction is shown in Figure 6. After complete
reaction, all liquid was then aspirated from the plate and the samples were rinsed three
times with deionized water.
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Figure 6: Schematic representation of bishydrazide attachment to PLGA surface using
CDI chemistry

3.3.1 Quantification of Hydrazide Groups
To measure the number of hydrazide groups bound to each PLGA sample, modified
surfaces were reacted with 2,4,6-trinitrobenzene sulfonic acid (TNBS) (Sigma). Samples
were incubated at 70°C for 5 minutes with 0.1% TNBS in a 3% sodium borate solution
(Sigma). This resulted in the formation of a trinitrophenyl group, which was then
hydrolyzed by reaction with 1M NaOH at 70°C for 10 minutes. This hydrolysis produces
22

a yellow-orange color that is proportional to the number of trinitrophenyl groups and
therefore to the number of bishydrazides groups [43]. Color development was measured
at 450nm. A standard curve was generated for each of the bishydrazide, because their
presence causes a shift in the color development of the assay.
3.4 Protein Attachment
Two different proteins were attached to the modified biomaterials of interest.
Recombinant human vascular endothelial growth factor (VEGF) (R & D Systems,
Minneapolis, MN) was selected because it plays an important role in the angiogenesis
phase of wound healing [37]. It has also been found to play a role in bone regeneration
when in conjunction with BMPs [38]. Parathyroid hormone 1-34 fragment (PTH)
(Sigma) was also explored because of the presence of an N-terminal serine and its ability
to stimulate bone formation. After attachment, the amount of protein and protein
accessibility were measured with an immunoassay.

3.4.1 VEGF Attachment
VEGF is a glycoprotein and the carbohydrate residues near the middle of the chain can be
oxidized to aldehyde moieties with periodate [45, 50]. This particular protein is expressed
in Sf21 insect cells using a baculovirus system to allow for oxidation of asparagine, at
approximately the 75th amino acid residue [37, 51]. VEGF was reconstituted in PBS at a
concentration of 40µg/ml. Oxidation was carried out by allowing 250µl of 10mM
periodic acid (Aldrich) to react with the 250µl of the VEGF solution, in the dark at room
temperature for 45 minutes. The reaction was quenched by adding 500µl glycerol. The
solution was then filtered by centrifuging for a total of 100min at 10,000rpm, and
washing with PBS. The VEGF was then resuspended in 500µl of PBS, the final volume
was then increased to 10ml. A volume of 250µl of the resuspended oxidized VEGF was
added to each PLGA sample, allowing the aldehyde groups to react with the hydrazide
groups at neutral pH to form stable hydrazone bonds [52]. VEGF was also randomly
adsorbed onto an unmodified PLGA surface by interaction of 250µl of VEGF solution
with each sample. The protein was allowed to react with each surface for 45 minutes at
23

room temperature. One set of samples was used for immediate data collection. A second
set of coverslips was prepared at the same time, and immediately following protein
attachment, the plates were incubated overnight at 37°C. A schematic representation of
glycoprotein oxidation and attachment to the modified surface is shown in Figure 7.
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Figure 7: Schematic representation of VEGF attachment to bishydrazide modified PLGA
surfaces

3.4.2 MicroBCA Analysis
The amount of VEGF protein bound to the PLGA surface was measured using a
MicroBCA kit (Pierce, Rockford, IL) following the manufacturer’s instructions. The
VEGF on the surfaces was allowed to interact with a working reagent solution that
undergoes a color change in the presence of protein. A standard curve was generated
using dilutions of a bovine serum albumin (BSA) standard. Color development was
measured at 570nm.

3.4.3 Binding Accessibility
The availability of VEGF for potential binding with cell receptors was assessed using an
immunoassay technique. All samples were blocked with a protein solution, BSA/PBST,
solution to prevent nonspecific antibody binding. BSA/PBST is a 0.5% BSA solution
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prepared in a solution that is 0.05% Tween 20 in PBS. A primary antibody to VEGF,
anti-VEGF purified mouse monoclonal IgG2B (R & D Systems), was reconstituted in PBS
and then diluted at a ratio of 1:500. A volume of 0.5ml of this primary antibody was
allowed to react with the samples for 30 minutes at 37°C and then washed with PBST
three times. The secondary antibody, alkaline phosphatase activated goat anti-mouse IgG
(Sigma), was diluted with PBS at a ratio of 1:500 and 0.5ml of antibody solution was
added to each sample. The secondary antibody was then allowed to react with the surface
for 45 minutes at 37°C and washed with PBST three times. A solution of 0.1% Sigma
104 phosphatase (Sigma) in 10% diethanolamine (Chempure, Houston, TX) at pH 9.8
reacted with the samples for a minimum of 20 minutes but ranging up to 60 minutes to
ensure maximum color development. Color development was measured at a wavelength
of 410nm.

3.4.4 PTH Attachment
PTH is a peptide that has an N-terminal serine that can be oxidized to an aldehyde moiety
with periodate [45, 50, 53]. PTH was reconstituted in PBS at a concentration of 40µg/ml.
Oxidation was carried out by allowing 250µl of 10mM periodic acid (Aldrich) to react
with the 250µl of the PTH solution, in the dark at room temperature for 45 minutes. The
reaction was quenched by adding 500µl glycerol. The solution was then filtered by
centrifuging for a total of 100min at 10,000rpm, and washing with PBS. The oxidized
PTH was then resuspended in 500µl of PBS, the final volume was then increased to
10ml. A volume of 250µl of the resuspended oxidized PTH was added to each PLGA
sample, allowing the aldehyde groups to react with the hydrazide groups at neutral pH to
form stable hydrazone bonds [52]. PTH was also randomly adsorbed onto an unmodified
PLGA surface by interaction of 250µl of PTH solution with each sample. The protein
was allowed to react with each surface for 45 minutes at room temperature. A schematic
representation of peptide oxidation and attachment to the modified surface is shown in
Figure 8.
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Figure 8: Schematic representation of PTH attachment to bishydrazide modified PLGA
surfaces

3.4.5 MicroBCA Analysis
The amount of VEGF protein bound to the PLGA surface was measured using a
MicroBCA kit following the manufacturer’s instructions. The PTH on the surfaces was
allowed to interact with a working reagent solution that undergoes a color change in the
presence of protein. A standard curve was generated using dilutions of a BSA standard.
Color development was measured at 570nm.

3.4.6 Binding Accessibility
The availability of PTH for binding with cell receptors was measured using an
immunoassay technique, using the same procedures as in the VEGF experiments. In these
experiments, however, two different polyclonal antibodies to PTH were used. One of the
antibodies has a binding epitope at the N-terminus of the peptide (sc-9676) and the other
had a binding site at the C-terminus (sc-9677) (Santa Cruz Biotechnology, Santa Cruz,
CA). All samples were blocked with BSA/PBST to prevent nonspecific antibody binding.
One of the two antibodies was diluted with PBS at a ratio of 1:500 and was allowed to
react with the samples for 30 minutes at 37°C and then washed with PBST three times.
The secondary antibody, alkaline phosphatase activated goat anti-mouse IgG (Sigma),
26

was diluted in PBS at a ratio of 1:500 was then allowed to react with the surface for 45
minutes at 37°C and washed with PBST. The remainder of the procedure was the same as
in the VEGF binding assessment.

3.5 Statistical Analysis
Statistical analysis was performed using INSTAT3 software (Graphpad Software Inc.).
One-way ANOVA was performed to determine if there were statistical significances in
the differences between mean values of measured parameters for the various
experimental groups. The Tukey Kramer multiple comparison test was used to compare
the different experimental groups.

27
Copyright © Jessica Bennett Lynn Sharon 2005

4. RESULTS

4.1 Material Characterization
Initially microspheres were prepared by double emulsion and simply adding polymer
solution dropwise to a spinning solution of 1% PVA. This resulted in microspheres which
were broken and fragmented, as shown in Figure 9. A few intact microspheres seemed to
have high porosity, but most of the microspheres were too fragmented to be used in
preparing scaffolds, as the porosity of the scaffolds would be changed by the presence of
these fragments. Instead, other techniques were explored to find a protocol that would
yield intact particles.

Figure 9: Fractured microspheres prepared from a double emulsion technique

Using a single emulsion technique, but delivering the polymer solution directly to the
bottom of a 1% PVA solution by stirring the solution at a minimum of 700rpm, resulted
in spherical particles, as shown in Figure 10. The microspheres had a very large range of
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sizes from 10-250 µm. However, since all particles were spherical, this method of
microsphere preparation was settled on, as the particle size could be controlled in the
preparation of scaffolds. Using smaller microspheres with larger microspheres and even
fragments could result in some of the smaller microspheres “clogging” the pores that
would be formed by using microspheres of the same size range. In order to prevent this,
microspheres were sieved using mesh sizes 45, 60 and 80 (US Standard sizes) to generate
a range from 50-150 µm, which is demonstrated in Figure 11. These microspheres were
used to prepare scaffolds.

Figure 10: In tact microspheres prepared from a single emulsion technique
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Figure 11: Sieved microspheres used to prepare scaffolds

The initial scaffolds were prepared by placing 50mg of the sieved microspheres into a
mold and then heating at 50°C for three days. This temperature was chosen, because it
was found to be high enough above the polymer’s glass transition temperature of 41.3°C
to yield a porous scaffold with reasonable strength, determined qualitatively. Using too
high of a temperature, even for a short period of time, yielded a very glass-like scaffold,
with very low porosity, measured using a displacement method. As mentioned
previously, Archimedes method was used to quantify porosity. However, instead of water
as the solvent for immersion, ethanol was used due to the hydrophobicity of the polymer.
Using ethanol instead of water resulted in more of the liquid entering the pores of the
scaffolds to allow for better measurement [49]. The 50mg scaffolds prepared by heating
at 50°C for three days, were of diameter 5.8 ± 0.16 mm with a height of 1.8 ± 0.11 mm.
These had an approximate porosity of 70%. The approximate ultimate compressive
strength of these scaffolds was 0.2893 ± 0.377 MPa and a compressive modulus of
4.4742 ± 3.69 MPa. Porosity was confirmed by SEM, as shown in Figure 12. These
scaffolds showed high amount of porosity, through the fusion of adjacent microspheres.
This fusion allowed for the creation of many pores and several pores of 100µm and larger
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in size was found. This pore size is required for osteons to build bone in these pores of
the scaffold [54].

Figure 12: SEM of 50mg scaffold prepared by heating for three days at 50°C

The 50mg scaffolds did seem desirable, until they were put into a cell culture medium
prior to starting cell culture experiments. The 50mg scaffolds simply released too much
acidic products as they degraded, which could not be controlled with buffers that were
safe for cell culture. Thus, smaller scaffolds were necessary. A mass of 25mg of sieved
microspheres were placed in the existing mold and heated at 50°C for three days. The
result was a very thin scaffold of approximate height of 0.5-0.75mm, with some scaffolds
having a ramp-like structure. These samples seemed to have very little strength, so a
different mold had to be developed, and it was found that a diameter of 4 mm resulted in
a strong scaffold that also had porosity. Scaffolds were prepared by heating at 50°C for
one, two or three days. Other temperatures were explored qualitatively for strength to
determine if the temperature had been too low or too high. When too high of a
temperature was used (greater than 53°C), scaffolds were extremely glassy and seemed to
have very little porosity. Temperature too low (less than 45°C) resulted in seemingly high
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porosity but crumbled upon any force, including removing them from the mold. Scaffolds
were examined with SEM and compression testing to determine the time of heating.
Figures 13, 14 and 15 show SEM images from the different heating times. As shown in
the SEM images, all scaffold preparations were found to produce porosity, with
interconnected pores larger than the minimum 100µm. As shown in Figure 13, the
scaffold that was heated for one day, the microspheres were only fused at a few contact
points. More fusion was shown after heating for two days, as shown in Figure 14, and
further fusion of adjacent microspheres after heating for three days, as shown in Figure
15. Increased fusion between microspheres should translate to higher strength in
compression for scaffolds.

Figure 13: Scaffold prepared with 25mg of microspheres and heated for one day at 50°C
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Figure 14: Scaffold prepared with 25mg of microspheres and heated for two days at 50°C

Figure 15: Scaffold prepared with 25mg of microspheres and heated for three days at
50°C
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The 25mg scaffolds were tested in compression. Table 1 and Figure 16 summarize the
results of this experiment. As the length of time that scaffolds were heated increased, the
compressive strength and modulus both increased as adjacent microspheres fuse together.
The scaffold heated for three days had a significantly higher compressive strength than
the other preparations (p<0.001) and the compressive modulus increased with increasing
length of heating.

Table 1: Compressive strength and modulus of 25mg PLGA scaffolds heated for one, two
or three days at 50°C
Time of Heating Compressive Strength (MPa)
1 day
0.085 ± 0.082
2 days
0.292 ± 0.207
3 days
0.661 ± 0.119

Compressive Modulus (MPa)
4.702 ± 4.677
5.014 ± 3.061
6.718 ± 1.468
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Figure 16: Compression testing results for 25mg scaffolds (*denotes significant
difference)
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Porosity of the 25mg scaffolds was measured in the same way as the 50mg scaffolds
were. As the length of heating increased, the porosity decreased, but no scaffolds had
porosity below 70%. There were no significant differences in the porosities. The porosity
data for the three different heating times are presented in Table 2.

Table 2: Porosity of 25mg scaffolds heated for one, two or three days at 50°C

Time of Heating Porosity (%)
1 day
75 ± 10
2 days
74 ± 6
3 days
71 ± 7.5

The surface area was measured with nitrogen gas adsorption. Results of this are shown
below in Table 3. The surface area decreased as heating time was increased.

Table 3: Surface area of 25mg scaffolds heated for one, two or three days at 50°C

Time of Heating

Surface Area
m /g
cm2/scaffold
2

1 day

0.035 ± 0.0059

8.76 ± 1.48

2 days

0.012 ± 0.0053

3.13 ± 1.33

3 days

0.0094 ± 0.02

2.35 ± 5.00

Using results of SEM images, compression testing, porosity and surface area scaffolds
should be prepared by heating 25mg of PLGA microspheres for three days at 50°C. In
addition, acid released by these scaffolds is more easily controlled.

4.2 Surface Modification
The carboxyl groups at the end of the polymer chains were modified with bishydrazides
using EDAC/NHS chemistry for both coverslips and scaffolds. Using coverslips coated
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with a polymer solution allowed for simple measurements of surface area and ease of
preparation.
Coverslips had a surface area of 113mm2. Equimolar concentrations for each of the
spacers were first used to ensure that each of the spacers had the same number of
hydrazide groups to interact with PLGA. This allowed examination of the effect of length
on the density of spacers could be studied. Using a concentration of 0.057mM, each
bishydrazide was successfully attached to the PLGA surface. As shown in Figure 17, the
same concentration for each of the spacers resulted in different number of groups. The
shorter spacer molecule, oxalic bishydrazide, was bound in much larger quantities, at
least five times more hydrazide groups than other treatments, despite an equal number of
groups for each bishydrazide. In fact, the oxalic bishydrazide was significantly different
(p< 0.01) than the other treatments. The other treatments were not significantly different
from the others. Based on the differences in binding for each of the different spacer

2000

2

Hydrazide Groups per nm xxx

lengths, more concentrations were investigated.

1500
1038
1000
500

200
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C6

C10

0
C2

C4

Bishydrazide Treatment

Figure 17: Surface modification using the same concentration for all bishydrazide spacers

Six equimolar concentrations for each of the bishydrazides were investigated so
treatments that yield the same number of groups for each of the bishydrazides could be
identified. However, due to differences in the lengths of the spacers, equimolar
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concentrations over a large range did not yield the same number of groups per surface
area. This is demonstrated in Figures 18 and 19 and summarized in Table 4.

A great deal of variability was found in the shortest and longest spacers due to solubility
issues with these solutions. For concentrations of 0.018, 0.057 and 0.115mM, the C10
spacer, sebacic bishydrazide produced a significantly greater number of hydrazide groups
bound to PLGA (p<0.05 compared to 0.018mM, and p<0.001 for 0.057mM and
0.115mM). In order to work with this spacer, though, solutions had to be prepared well in
advance of use and with rapid spinning to ensure that all of the bishydrazide stayed in
solution, and plates were shaken rapidly in order to keep most of the spacer in solution.
C2, oxalic bishydrazide, also had slight problems with solubility, but was easier to keep
in solution with extended spinning time and rapid plate shaking during the modification.
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Concentration (mM)

Figure 18: Surface modification of PLGA coverslips with varying concentrations of
bishydrazides (*denotes significant difference from other spacers at same concentration)
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Figure 19: Expanded figure for surface modification of PLGA coverslips with varying
concentrations of bishydrazides

Table 4: Summary of number of groups bound to PLGA surface for each of the
bishydrazide spacers and each concentration

Concentration (mM)
0.002
0.011
0.018
0.057
0.115
0.184

C2
18
36
17
31
103
1125

Groups per nm2
C4
C6
1
30
37
48
14
30
87
143
369
199
390
476

C10
20
102
138
531
1036
904

Based on the results from using many different concentrations for each of the
bishydrazide spacers, concentrations could be chosen that would result in a similar
number of hydrazide groups for each spacer length. With an equal number of groups for
each of the spacers, the effect of the length on protein attachment could be studied. Using
results from previous experiments and experience with the methods, bishydrazide
concentrations shown in Table 5 were selected. Using these various concentrations
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resulted in comparable number of groups for each of the spacers, as presented in Figure
20. Using different concentrations for each of the different spacers resulted in
approximately 50 groups per nm2 for each of the different treatments of the coverslips.
The result was a control of the number of hydrazide groups per unit surface area despite
varying lengths between the spacers. None of these groups were significantly different
from each other.

Table 5: Concentrations for each of the spacers used to generate an equal number of
hydrazide groups for each

Spacer
C2
C4
C6
C10

Concentration (mM)
0.018
0.057
0.018
0.011

2

Hydrazide Groups per nm

160
120
80
50

59
41

51

40
0
C2

C4
C6
Dihydrazide Treatment

C10

Figure 20: Equal number of groups per surface area for each spacer

39

4.3 Protein Attachment

4.3.1 VEGF Attachment
The success of binding VEGF to the surface of modified and unmodified PLGA
coverslips was assessed using both the quantitative amount of protein bound as well as a
technique to measure the accessibility of VEGF for binding to antibody. These results
were measured immediately after attachment and after incubation for 12 hours in PBS at
37°C. VEGF was successfully bound to all modified and unmodified surfaces. In this
experiment the number of hydrazide groups decreased as spacer length increased.

The amount of protein bound to each surface is presented in Figure 21. The amount of
protein bound to coverslips was the highest for the shortest and longest spacer chains, C2
(oxalic) and C10 (sebacic), respectively. The C2 group resulted in a significantly higher
amount of protein than the C4 (succinic) or C6 (adipic) (p<0.05). The amount of VEGF
on the hydrazide-modified surfaces was generally larger than on untreated PLGA. The
C2 and C10 modified coverslips had an amount of protein which was significantly
different than that of randomly adsorbed protein on PLGA (p<0.05). After overnight
incubation, the amount of protein bound to the modified surfaces decreased. Also, the
variability within each group decreased as this loosely bound protein was reduced.
Interestingly, the amount of protein bound to the surface of unmodified PLGA actually
increased. The variability for adsorbed protein also increased.
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Figure 21: Amount of VEGF bound to modified and unmodified PLGA surfaces initially
and following overnight incubation in PBS

The accessibility of VEGF for antibody binding is presented in Figure 22. Antibody
binding was the greatest on the C2 modified surface and decreased as the spacer length
increased. However, the amount of binding was not significantly different for any of the
different treatment groups. A high amount of variability in antibody binding was
observed for protein simply adsorbed on untreated PLGA surfaces. The accessibility of
VEGF for antibody binding was also measured following overnight incubation. Both the
initial and incubation binding results are presented in Figure 22. The accessibility for
antibody binding was similar for all surfaces and variability within samples was also
decreased following incubation.
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Figure 22: Antibody binding of VEGF bound to modified and unmodified PLGA surfaces
initially and following overnight incubation in PBS

A comparison between the initial amounts of VEGF bound to the each surface and the
accessibility of VEGF for antibody binding is presented in Figure 23. The shortest spacer,
C2 had both the highest amount of bound protein as well as the highest amount of
accessibility. Significant variability was seen for these two groups.
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Figure 23: Amount of VEGF and accessibility of bound VEGF when bound to PLGA by
bishydrazide spacers immediately following VEGF attachment

Figure 24 summarizes both the amount of bound VEGF as well as the accessibility for
binding following 12 hour incubation in PBS at 37°C. All groups showed a similar
amount of bound VEGF despite different numbers of hydrazide spacer groups. The
accessibility for binding was also similar for all groups. Variability was also decreased
with the overnight incubation.
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Figure 24: Amount of VEGF and accessibility of bound VEGF when bound to PLGA by
bishydrazide spacers after incubation in PBS for 12 hours at 37°C

4.3.2 PTH Attachment
PTH was successfully bound to all modified and unmodified surfaces. The success of
binding PTH to the surface of modified and unmodified PLGA coverslips was measured
using both a quantitative amount of protein bound as well as a technique to measure the
accessibility of PTH for binding to antibody. The modified surfaces were controlled such
that all of the surfaces, regardless of the spacer length, had a similar number of groups
per surface area, equal to approximately 50 hydrazide groups/nm2. This allowed the study
to determine the effects of the length of spacers on protein attachment.

The amount of PTH bound is presented in Figure 25. The amount of PTH attached to the
four hydrazide-derivatized surfaces was statistically the same at about 0.5 µg. The spacer
length did not play a role in the amount of protein that was able to bind to the modified
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coverslips. PLGA with randomly adsorbed peptide had a similar amount. The use of a
spacer in general did not improve protein attachment to PLGA coated coverslips.

Amount of PTH (µg)xxxxxx
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Adsorb
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Figure 25: Amount of PTH bound to modified and unmodified surfaces using equal
number of hydrazide groups for modification

The PTH antibody binding results are presented in Figure 26. In contrast to the amount of
bound protein, the use of a spacer improved accessibility of the N-terminus, which was
used for immobilization. Antibody binding to an N-terminal epitope was significantly
greater on all four hydrazide-derivatized surfaces compared to the random surface. In
contrast, availability of the free C-terminus of PTH was statistically similar on all five
surfaces, but with a trend of lower accessibility on the random surface.
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Figure 26: Antibody binding of PTH bound to modified and unmodified surfaces using
equal number of hydrazide groups for modification (* denotes significant difference)
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5. DISCUSSION

5.1 Materials
Microspheres showed very similar properties to those prepared using a non-loaded
double emulsion technique, as reported by Schrier and DeLuca [20, 34]. Microspheres
had a general nonporous surface with a spherical shape and varying size ranges.
Microspheres were found to require specific conditions of preparation. Simply adding the
polymer solution to PVA dropwise at the top of the beaker did not result in spherical
particles, because when the polymer is added to solution, the force of the droplet hitting
the surface must be high enough to break that drop into microspheres in the solution.
Only adding to the top surface of the PVA solution resulted in fragmented and misshapen
microspheres. However, if the polymer solution was added directly to the bottom of the
PVA solution, the force was high enough to create spherical microspheres with a
nonporous surface. As Ma et al found, the rate of spinning of the microspheres had an
effect on the size range of particles formed [12]. Using a stir rate of 600rpm overnight
resulted in microspheres within the desired size range for preparation of scaffolds to
create a minimum pore size of 100µm required for bone formation into the scaffold [54].

As previously mentioned, the initial scaffolds investigated were 50mg. When these
scaffolds were placed into cell culture medium, they were found to release too much acid
too quickly for the buffer to maintain a constant pH, which is required for control of
cellular experiments. As polymer degrades it breaks into different monomers and
oligomers of lactic and glycolic acids with terminal carboxyl groups exposed following a
chemical hydrolysis of ester bonds, in which both the rate of release and amount of acid
decreases the pH [42]. The pH must be controlled using a concentration of buffer that is
not detrimental to the cells [42, 55]. The amount of acid released from PLGA implants is
controlled in the body, but too much acid that is not controlled may cause an
inflammatory response and negate the purpose of the specific implant [42]. If the amount
of acid present is controlled in vitro in cellular experiments, it can be theorized that the
amount of acid could then be controlled when the implant is placed in vivo. Because of
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this problem for in vitro experiments, however, the mass of polymer was decreased from
50mg to 25mg. Initially 25mg scaffolds were placed into the same mold that was used to
prepare the larger scaffolds. The use of this mold with the same preparation conditions
resulted in a very thin scaffold. These thin scaffolds did have seemingly high porosity but
were so thin that the strength would have been extremely low, in addition to difficulty in
controlling the shape. A majority of these thin scaffolds had a ramp like top surface.
Based on this, a new mold that would generate an acceptable size scaffold was prepared.

Scaffolds can be prepared a number of different ways, from salt leaching to gas foaming
to simple heating [7, 56]. All of these methods result in stable scaffolds, but since heating
is a very simple technique it was used for the preparation in this work. When temperature
is increased, thermal fusion of adjacent microspheres at their contact points occurs [7].
The nature of this preparation technique allows for 100% pore interconnectivity due to
the behavior microsphere fusion [7]. Even a slight increase in temperature above the glass
transition temperature of the polymer can result in a scaffold with high porosity but very
little strength. High temperatures result in a very glassy scaffold as expected, with very
little porosity but high strength. Time was also found to play a role in the strength and
porosity of the scaffolds. The challenge was to find a balance between the mechanical
strength of the scaffold and a high porosity. Cancellous bone has been found to have a
compressive modulus between 2 and 2000 MPa and approximately a 70% pore volume,
depending on where the sample is taken from [7, 27, 54]. The mechanical strength was
tested in compression. The 50mg scaffold had a compressive strength of 0.2893 MPa and
a modulus of 4.4742 MPa. Borden et al reported sintered scaffolds, prepared by heating
for 24 hours 5°C above Tg, with a compressive modulus of approximately 349MPa.
However, these scaffolds were prepared using a PLGA with a ratio of LA:GA of 58:42
[7]. In another study, Borden et al presented the compressive modulus for PLGA with a
ratio of LA:GA of 85/15 as approximately 272MPa. These scaffolds were prepared by
heating microspheres for four hours at approximately 100°C above Tg [7]. These values
are within the range of compressive modulus for cancellous bone, so these scaffolds
could be used for a bone replacement. The porosity was 70% which matches the
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approximate porosity of natural bone. This is important because bone needs to grow into
the scaffold and a high amount of porosity is required.

The same conditions of heating were also explored for the smaller scaffolds. They were
heated at 50°C for one, two or three days, and the final scaffold was tested for mechanical
strength, porosity and examined using SEM. As expected, as mechanical strength
increased the porosity decreased, which was in response to the heating time. All scaffolds
appeared to maintain minimum pore sizes of 100µm as seen through SEM images. This is
the minimum size pore to allow for bone growth throughout the scaffold which is the
only way for the scaffold to be replaced with natural bone. The porosity of the scaffolds
decreased with increasing time of heating. As the length of time increased, more adjacent
microspheres were able to fuse together to form a structure with less porosity. However,
in contrast, the longer heating times resulted in a stronger scaffold from the fusion of
microspheres. Based on the high porosity and greater compressive strength, the scaffold
that was heated for three days was selected for this study.

5.2 Surface Modification
Many PLGA chains are synthesized with an end-cap, so that there are no exposed
functional groups. However, the polymer used in this study was non-endcapped, leaving
an exposed carboxyl group at the end of the chain. This made modification of the PLGA
chains simple with many and accessibility of functional groups. Surface modification
was carried via CDI to couple varying length spacers of bishydrazide groups to the
carboxyl group on PLGA. The four different lengths of the spacers varied in their ease of
use. Variability is explained by solubility differences between the different spacers, for
example, as the length increased the solubility decreased making it difficult to keep the
spacer in solution. The increasing length of carbon chains and the use of an acidic
solution only make the solubility issues more difficult to control. However, this was
remedied by preparing solutions about an hour before needed and maintaining a high rate
of stirring or shaking while the solution was in use.
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Using the same concentration for each of the spacers resulted in a decreasing number of
hydrazide groups with increasing spacer length. Because the concentrations were on a
molar basis there were equal numbers of molecules available to react with PLGA for each
different bishydrazide. With the decreasing number of groups it can be deduced that more
competition between the longer spacers, as well as steric hinderance, resulted in fewer
bishydrazide molecules attached. The bishydrazide molecule has a hydrazide group at
each end, and with increasing length and less competition in dilute solutions it is possible
for both ends of the spacer to attach to an activated carboxyl group at the end of the
PLGA chain. These molecules are then not able to react with TNBS in a detection assay
and therefore would not be detected. The shorter chains did not seem to have these
problems.

Using several concentrations of each spacer allowed for the development for a large
matrix of concentration and number of bishydrazide groups. This matrix was developed
as a method for controlling the number of groups on any modified surfaces. The ultimate
goal was to fix either the density or length independent of one another.

Control of the number of groups was demonstrated through the surface modification of
coverslips for the eventual attachment of PTH. Different concentrations were used for
each of the spacers to result in an average surface density of hydrazide groups of 50 per
nm2 of nominal surface area. The relative similarity in surface density allowed
comparison of the effect of spacer length on peptide immobilization and antibody
accessibility. The similarity in surface density of bishydrazide molecules also
demonstrated that the length and density of any spacer could be controlled independently
of one another. Effectively, the density could be fixed to study the dependence of protein
binding on the spacer length, and vice versa.
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5.3 Protein Attachment

5.3.1 VEGF Attachment
VEGF was successfully bound to both unmodified and hydrazide-modified PLGA
coverslips. When comparing different densities and lengths of the spacers in response to
protein attachment, the shortest and longest spacers resulted in the highest amount of
protein. The high amount of protein bound to the C2 spacer likely relates to the number
of hydrazide groups available for binding since surface density decreased as spacer arm
increased. The C10 spacer also had a high amount of protein attached to it, due to the
flexibility of the spacer for protein binding. However, it is also important to note that the
amount of protein bound to each hydrazide-modified coverslip was higher than the
amount of VEGF bound to untreated PLGA. It was then determined that the use of a
spacer improved protein attachment regardless of the length or density of hydrazide
groups. The amount of protein had been measured at two different time points, both
immediately after protein attachment and after incubation overnight in PBS. The amount
of protein attached to each coverslip did not change overall, but the variability in the
groups did decrease, as was expected. If the protein was covalently bound to the surface
of PLGA by means of a spacer molecule, a great deal of protein should not have been
lost; however, the loosely bound VEGF molecules were desorbed from the surface.
Therefore the use of hydrazide spacers for protein attachment onto PLGA was validated.

The antibody binding was also measured at both time points. The accessibility of protein
for binding was the highest on the shortest spacer, oxalic bishydrazide, and decreased
with increasing length. These results likely relate not only to the length and flexibility of
the spacer but also the number of hydrazide molecules available for binding, since the
surface density decreased as the spacer arm increased. Significant variability was found
for the protein simply adsorbed onto the untreated PLGA surfaces. After incubation, the
antibody binding was similar for all surfaces, and again the variability decreased. The
decrease in variability was the result of loss of weakly bound protein from the samples.
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Carbohydrate residues on VEGF were successfully oxidized to form aldehyde moieties
for interaction with hydrazide groups attached to PLGA. However, in VEGF165, the site
of carbohydrate oxidation is close to the binding sites on VEGF. The oxidation site is at
approximately the 75th amino acid residue and the cell-receptor binding sites are located
on both sides of oxidation site at approximately the 50th and 100th amino acids [51]. The
oxidation of the carbohydrate residues could then result in some changes in the binding
sites of the chain since they are so close. In addition, with the attachment site of the
protein to the spacer so close to the binding sites, steric effects could cause some of the
cell-receptor binding sites to be unavailable.

Use of a spacer arm between immobilized VEGF and PLGA can result in better
availability of the growth factor for antibody binding, which may translate to better
interaction with VEGF receptors on cells that encounter the modified surface.

5.3.2 PTH Attachment
For the experiments on PTH attachment, the spacer length was the primary variable under
investigation. Based on previous experimentation, different concentrations of the
bishydrazides were chosen to result in a similar number of groups on each derivatized
surface. This was in order to investigate the effects of the length of different
bishydrazides to determine its effect on peptide immobilization and antibody
accessibility. Selected concentrations resulted in an average surface density of hydrazide
groups of approximately 50 per nm2 of nominal surface area for each spacer length.
When using the similar density of groups, it was found that the amount of protein bound
to the surface of each coverslips was approximately equal, as was the amount randomly
adsorbed on PLGA.

Antibody binding was measured for two different PTH antibodies, one which measures
the accessibility of the C-terminus of PTH and one which measured the N-terminus of
PLGA. The C-terminus showed statistically similar binding on all surfaces but a trend of
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lower accessibility on the random surface. In contrast, the accessibility of the N-terminus,
which was used for immobilization, was significantly greater on all four of the hydrazidederivatized surfaces in comparison to the random surfaces. This increased antibody
binding may translate to better interaction with PTH receptors on cells that encounter the
modified surface. Again, binding could have been further investigated with overnight
incubation PTH. Most likely, the binding should not change for any of the modified
surfaces and decrease for the random PLGA surface, as the protein attached to the
spacers should be bound more tightly than the amount simply adsorbed on PLGA.

5.4 Context
The primary objective of this study was to determine the effects of site-directed
immobilization of growth factors onto PLGA materials. However, in order to do this,
PLGA materials had to be developed according to current literature. PLGA coatings,
microspheres and scaffolds were fabricated using a single-emulsion technique and
scaffolds were prepared using a sintering method similar to that reported by Borden,
Schrier, and Ma [7, 12, 20, 34, 57]. Scaffolds were prepared to have compressive strength
and porosity for use as a bone replacement similar to those of trabecular bone, though on
the lower end of the range of compressive strength [7, 27, 54]. In order to achieve the
goals of the study, coatings and scaffolds were modified to act as delivery vehicles for
growth factors using site-directed immobilization.

Non end-capped PLGA provides available carboxyl group for modification of the
polymer chain. Site-directed immobilization requires the tailoring of both the biomaterial
and biomolecule. The surface modification of PLGA was performed using CDI, which is
a widely used method of coupling an amine to a carboxyl group [33, 43, 46].
Bishydrazide spacer molecules were used to covalently attach a protein to the surface of
PLGA, rather than randomly adsorb protein onto the polymer surface. Hydrazide
modification of surfaces allows for attachment of periodate-activated carbohydrates, as
used in this study. The use of the bishydrazide spacer results in more sensitivity to cell
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binding sites and correlates to an increase in binding activity in comparison to
unmodified surfaces, in a report by Veilleux [58]. Veilleux and Duran performed a study
in which polystyrene plates were activated with hydrazide. The plates were then reacted
with a periodate-activated alkaline phosphatase that normally would not be reactive
towards polystyrene plates. The amount of protein immobilized on the activated surfaces
was considerably higher than what would bind to an unmodified surface. In the present
study, similar results were also observed in studying the binding accessibility of VEGF
and PTH bound to the surface of PLGA using a hydrazide spacer. Currently there have
not been many studies in the immobilization of VEGF or PTH onto PLGA scaffolds.
Instead, these proteins have primarily been encapsulated into PLGA microspheres for a
controlled release and gene therapy. Sofia et al used a silk based scaffold for
immobilization of PTH hormone, using CDI chemistry. The scaffolds modified with PTH
showed increased osteoblasts adhesion as compared to plastic. Thus, immobilization of
PTH onto scaffolds was able to elicit a response towards bone regeneration [59]. The
present research took the immobilization one step further to actually use site-directed
immobilization of VEGF and PTH onto a scaffold through surface modification of PLGA
using bishydrazide chemistry.

Using this site-directed immobilization with or without spacer molecules resulted in more
protein bound to the modified surface rather than unmodified. Immobilization of growth
factors or proteins, whether site-directed or random, results in a higher amount of bound
protein as reported by Puleo and Yoo. Puleo et al coupled amine groups to the surface of
titanium alloy, and then randomly immobilized BMP to the surfaces. This resulted in a
higher amount of activity than protein that was simply adsorbed onto the alloy surface
[43]. Yoo et al reported increase in collagen synthesis from immobilized HA onto the
surface of modified PLGA implants. Cellular attachment to the implants was improved
[46].

In these present studies, both VEGF and PTH were more accessible for antibody binding,
indicating that they would be available for interaction with the receptors on cells. In
addition, the covalent attachment of VEGF onto the PLGA surfaces allowed for protein
54

to remain bound following incubation in PBS. As Schrier reported, growth factor
concentrations must be maintained at the site of implant in order to induce a specific
cellular response [13, 20, 25]. The use of site-directed immobilization allows for control
over the concentration of growth factor on the surface of the implant, and the material
properties control the length of time that the growth factor is maintained at the site, as
PLGA releases growth factors as it degrades [9, 34, 42, 48].
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6. CONCLUSIONS

PLGA materials can be fabricated into coatings, microspheres and scaffolds for
implantation into the body depending on the site of implantation. For bone biomaterials,
PLGA scaffolds can be very useful because each scaffold can be fabricated to match a
specific defect in bone, for example, filling in fracture nonunions. In addition, functional
groups at the end of the polymer chain can be utilized for surface modification and
growth factor attachment to the material prior to implantation.

Bishydrazide chemistry was used to modify the carboxyl group at the end of the polymer
chain. Four different bishydrazides were successfully attached to the PLGA materials.
These four spacers were of varying length, and the length and density of the surface
groups were studied to determine each variable’s effect on protein binding. The use of a
spacer improved protein binding rather than protein simply adsorbed onto a PLGA
surface. Short and long spacer arms had the highest amount of protein binding, with
similar results for accessibility of the protein for antibody binding.

Both VEGF and PTH were used for protein binding measurements. Both of these proteins
are very different in their target cells as well as purpose, but this furthers the applications
of surface modified PLGA materials for site-directed immobilization of growth factors.
Using different growth factors can allow the polymer biomaterials to be applied to type of
implant, from vascular to bone implants.
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